Clinique

Search documents
Why Estee Lauder Could Be Your Next 30% Gain
Benzinga· 2025-07-10 19:25
Core Viewpoint - Estee Lauder Companies Inc. is set for a significant turnaround driven by its "Beauty Reimagined" strategy, despite recent challenges, particularly in Asia, with a forecasted stock price increase of 30% [1][2]. Group 1: Financial Performance and Projections - The company is expected to achieve a 4% revenue CAGR through fiscal year 2027 and a margin expansion of 430 basis points to 12%, with EBIT projected to be 10% above consensus [3]. - Earnings per share (EPS) have dropped by 80% from their peak due to weakness in Asia, particularly in China and Hainan, but improved demand is anticipated in the upcoming quarters [5]. - The current trading multiple of 2.4x EV/sales indicates a significant discount compared to peers like L'Oréal, suggesting potential for a re-rating of the stock [7]. Group 2: Strategic Initiatives - The "Beauty Reimagined" strategy focuses on innovation speed, new channels, and cost efficiency, with a potential 10% reduction in headcount yielding up to $1 billion in savings, which may be reinvested into a 25% increase in brand and consumer marketing [4]. - The company generates $14 billion in revenue across 25 brands, positioning itself as the second-largest player in the $160 billion global prestige beauty market [4]. Group 3: Market Conditions - A more rational market environment during key shopping festivals and stabilizing trends in Hainan are expected to support growth in fiscal year 2026, while Korea's travel retail segment faces ongoing pressure [6].
EL Q3 Earnings Beat Estimates, Sales Down Amid China Weakness
ZACKS· 2025-05-01 16:55
Core Insights - The Estee Lauder Companies Inc. reported third-quarter fiscal 2025 results with both net sales and earnings declining year over year, primarily due to weak consumer sentiment and reduced conversion rates in China [1][2] Financial Performance - Adjusted earnings were 65 cents per share, surpassing the Zacks Consensus Estimate of 29 cents, but down 33% from 97 cents in the prior year [2] - Quarterly net sales reached $3,550 million, exceeding the Zacks Consensus Estimate of $3,507.2 million, but reflecting a 10% decline year over year [2] - Organic net sales decreased by 9% to $3,605 million [2] Category-Wise Revenue Results - Skin Care sales fell 12% year over year to $1,807 million, impacted by weak consumer sentiment and lower conversion rates among Chinese shoppers [3] - Makeup revenues declined 9% to $1,035 million, primarily due to weaker sales from key brands like M·A·C and Estée Lauder [4] - Fragrance revenues decreased 3% to $557 million, largely due to lower performance from Clinique and Estee Lauder [4] - Hair Care sales totaled $126 million, down 12% year over year, mainly due to Aveda's weaker performance [5] Regional Revenue Results - Sales in the Americas fell 6% year over year to $1,052 million [6] - Revenues in the EMEA region declined 18% to $1,358 million [6] - Asia-Pacific region sales tumbled 3% to $1,140 million [6] Margin Analysis - Adjusted gross margin improved by 310 basis points to 75%, driven by the Profit Recovery and Growth Plan (PRGP) [7] - Adjusted operating margin contracted by 270 basis points to 11.4%, due to increased investments and sales volume deleverage [8] Financial Health - The company exited the quarter with cash and cash equivalents of $2,631 million, long-term debt of $7,298 million, and total equity of $4,345 million [9] - Net cash flow from operating activities for the nine months ended March 31, 2025, was $671 million, with capital expenditures of $395 million [10] Restructuring and Future Outlook - The PRGP aims to transform the operating model, with expected restructuring charges between $1.2 billion and $1.6 billion before taxes [12][13] - The company anticipates a decline in reported net sales of 8-9% for fiscal 2025, with adjusted organic net sales expected to fall by the same percentage [14] - Adjusted EPS is projected to slump by 40-50%, ranging from $1.30 to $1.55 for fiscal 2025 [15]
雅诗兰黛预计2026年将恢复销售增长
news flash· 2025-05-01 10:27
Core Viewpoint - The company, which owns The Ordinary and Clinique brands, expects a sales decline of 8% to 9% this year, which is worse than Wall Street's expectations [1] Group 1: Sales and Financial Performance - The anticipated sales decline is attributed to trade turmoil and a challenging economic outlook, exacerbating existing deep-rooted challenges faced by the beauty giant [1] - The company's stock rose by 5% in pre-market trading on Thursday, despite a year-to-date decline of 20% for Estée Lauder, compared to a 5.3% drop in the S&P 500 index [1] Group 2: Strategic Initiatives - The company has indicated early signs that its turnaround plan is showing effectiveness, suggesting potential for recovery if issues are adequately addressed [1] - Recent tariff measures have been implemented to mitigate potential negative impacts related to the economic challenges [1]